紫杉醇联合羟基喜树碱治疗晚期食管癌的临床疗效观察

目的 观察紫杉醇联合羟基喜树碱治疗晚期食管癌的近远期疗效和不良反应。方法70倒晚期食管癌患者随机被分为PH纽和NP组，PH纽采用紫杉醇联合羟基喜树碱治疗，NP纽采用长春瑞滨联合顺铂治疗方案。评价2组疗效和不良反应。结果①PH组有效率为47．1％，疾病控制率73．5％#NP方案有效丰为43．3％，疾病控制卒63．3％。2组比较差异无统计学意义（P〉0．0S）。②PH组患者生存率为29．4％，死亡卒为70．6％;NP纽生存率为26．7％，死亡率为73．3％，2组远期疗效比较差异无统计学意义（P〉0．05）。③2组均出现严重的白细胞减少和脱发现象，发生率〉90％，但PH纽Ⅲ～Ⅳ级发生卒量著低于NP纽（P〈0．05）;PH组出现关节肌肉痛和恶心呕吐的发生率和Ⅲ～Ⅳ级发生率均显著低于NP组（P〈0．05）。结论紫杉醇联合羟基喜树碱治疗吃期食道癌疗效确切，毒性反应可耐受，值得进一步临床应用和观察。

Clinical Therapeutic Effect of Paclitaxel Combined with Hydroxycamptothecin in Treatment of Advanced Esophageal Cancer

Objective To observe the clinical therapeutic effect and safety of Paclitaxel combined with Hydroxycamptothecin(HCPT) in treatment of advanced esophageal cancer. Methods 70 cases of advanced esophageal cancer patients were randomly divided into PH group and NP group. PH group was given treatment of Paclitaxel combined with HCPT, while the NP group was given treatment of NVB combined with DDP.The clinical ther apeutic 47.1%, disease control rate of 73.5%;NP group had efficiency of 43.3%, disease control rate of 63.3%, there was no significant difference(P>0.05) 70.6%; NP group survival rate was 26.7%, mortality rate was 73.3%,there there were serious leukopenia and hair loss situation,the incidence was>90%,but the PH group Ⅲ～Ⅳ level incidence was significantly lower than the NP group(P<0.05);PH group the incidence and grade Ⅲ～Ⅳ incidence of joint muscle pain,nausea and vomiting were significantly lower than the control group(P<0.05).Conclusion Paclitaxel combined with HCPT in treatment of advanced esophageal cancer is effective,adverse reactions can be tolerated,and it is worth further clinical research and extension.